A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

被引：0
|
作者：
Weiss, G. [1 ]
Donehower, R. [2 ]
Westin, E. [3 ]
Bence, A. [4 ]
Hynes, S. [5 ]
Hurt, K. [6 ]
机构：
[1] TGEN Clin Res, Canc & Cell Biol Div, Scottsdale, AZ USA
[2] Johns Hopkins Univ, Med Ctr, Baltimore, MD 21218 USA
[3] Eli Lilly & Co, Med Oncol Exploratory Preclin, Indianapolis, IN 46285 USA
[4] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Program Phase, Indianapolis, IN 46285 USA
[6] Eli Lilly & Co, Clin Oncol, Indianapolis, IN 46285 USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72223-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [11] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Ghamande, Sharad
    Lin, Chia-Chi
    Cho, Daniel C.
    Shapiro, Geoffrey I.
    Kwak, Eunice L.
    Silverman, Michael H.
    Tseng, Yunlong
    Kuo, Min-Wen
    Mach, Wendy B.
    Hsu, Shu-Chi
    Coleman, Teresa
    Yang, James Chih-Hsin
    Cheng, Ann-Lii
    Ghalib, Mohammad H.
    Chuadhary, Imran
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 445 - 451
  • [12] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Sharad Ghamande
    Chia-Chi Lin
    Daniel C. Cho
    Geoffrey I. Shapiro
    Eunice L. Kwak
    Michael H. Silverman
    Yunlong Tseng
    Min-Wen Kuo
    Wendy B. Mach
    Shu-Chi Hsu
    Teresa Coleman
    James Chih-Hsin Yang
    Ann-Lii Cheng
    Mohammad H. Ghalib
    Imran Chuadhary
    Sanjay Goel
    Investigational New Drugs, 2014, 32 : 445 - 451
  • [13] Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer
    Gomez, Henry L.
    Philco, Manuel
    Pimentel, Patricia
    Kiyan, Miriam
    Monsalvo, Maria Laura
    Conlan, Maureen G.
    Saikali, Khalil G.
    Chen, Michael M.
    Seroogy, Joseph J.
    Wolff, Andrew A.
    Escandon, Rafael D.
    ANTI-CANCER DRUGS, 2012, 23 (03) : 335 - 341
  • [14] Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
    Toshihiko Doi
    Narikazu Boku
    Yusuke Onozawa
    Keishiro Takahashi
    Osamu Kawaguchi
    Atsushi Ohtsu
    Investigational New Drugs, 2020, 38 : 1390 - 1399
  • [15] Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial
    Imamura, Keiko
    Izumi, Yuishin
    Nagai, Makiko
    Nishiyama, Kazutoshi
    Watanabe, Yasuhiro
    Hanajima, Ritsuko
    Egawa, Naohiro
    Ayaki, Takashi
    Oki, Ryosuke
    Fujita, Koji
    Uozumi, Ryuji
    Morinaga, Akiko
    Hirohashi, Tomoko
    Fujii, Yosuke
    Yamamoto, Takuya
    Tatebe, Harutsugu
    Tokuda, Takahiko
    Takahashi, Naoto
    Morita, Satoshi
    Takahashi, Ryosuke
    Inoue, Haruhisa
    ECLINICALMEDICINE, 2022, 53
  • [16] Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignancies
    Doi, Toshihiko
    Boku, Narikazu
    Onozawa, Yusuke
    Takahashi, Keishiro
    Kawaguchi, Osamu
    Ohtsu, Atsushi
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1390 - 1399
  • [17] A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients With Cancer
    Curtis, Kelly K.
    Hartney, Jean T.
    Jewell, Roxanne C.
    Park, Jung W.
    Lebowitz, Peter F.
    Griffin, Pamela P.
    Borad, Mitesh J.
    Fitch, Tom R.
    Northfelt, Donald W.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (03): : 268 - 275
  • [18] A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
    Qing Zhou
    Daniel Gustafson
    Sujatha Nallapareddy
    Sami Diab
    Stephen Leong
    Karl Lewis
    Lia Gore
    Wells A. Messersmith
    Anthony M. Treston
    S. Gail Eckhardt
    Carolyn Sidor
    D. Ross Camidge
    Investigational New Drugs, 2011, 29 : 340 - 346
  • [19] Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
    Issa, Jean-Pierre J.
    Roboz, Gail
    Rizzieri, David
    Jabbour, Elias
    Stock, Wendy
    O'Connell, Casey
    Yee, Karen
    Tibes, Raoul
    Griffiths, Elizabeth A.
    Walsh, Katherine
    Daver, Naval
    Chung, Woonbok
    Naim, Sue
    Taverna, Pietro
    Oganesian, Aram
    Hao, Yong
    Lowder, James N.
    Azab, Mohammad
    Kantarjian, Hagop
    LANCET ONCOLOGY, 2015, 16 (09): : 1099 - 1110
  • [20] A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer
    Zhou, Qing
    Gustafson, Daniel
    Nallapareddy, Sujatha
    Diab, Sami
    Leong, Stephen
    Lewis, Karl
    Gore, Lia
    Messersmith, Wells A.
    Treston, Anthony M.
    Eckhardt, S. Gail
    Sidor, Carolyn
    Camidge, D. Ross
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (02) : 340 - 346
12345